Skip to content

XOMA Corporation XOMA Asset Acquisition Contingent Value Rights Liability Current

Asset Acquisition Contingent Value Rights Liability Current at other companies

Unusual Machines logo
Unusual MachinesUMAC
$2.85M
WisdomTree logo
WisdomTreeWT
1,440,600,000%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$93.98M
Insmed logo
InsmedINSM
$270.31M+69.0%
Natera, Inc. logo
Natera, Inc.NTRA
$103.2M
Beam Therapeutics logo
Beam TherapeuticsBEAM
$5.45M+371%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept xoma:AssetAcquisitionContingentValueRightsLiabilityCurrent.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's asset acquisition contingent value rights liability current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's asset acquisition contingent value rights liability current?
XOMA Corporation (XOMA) reported asset acquisition contingent value rights liability current of $7.18M in Q1 2026.
What does asset acquisition contingent value rights liability current mean?
This represents the short-term liability associated with contingent value rights issued in connection with asset acquisitions. These rights entitle the holders to additional payments if specific future performance or clinical milestones are met. It provides transparency into the near-term financial impact of performance-based acquisition agreements.